City of Hope is at the
2026 ASCO® Annual Meeting
Join our experts at the annual meeting, May 29 to June 2 in Chicago, Illinois, as we highlight how City of Hope® is advancing cancer research and care. With outcomes that consistently exceed national estimates and one of the nation’s largest networks of advanced cancer centers, we bring academic‑level expertise and leading‑edge treatments closer to more patients and communities.
As a global leader in CAR T and cellular therapies, supported by on‑site manufacturing capabilities and a robust national clinical trials network, City of Hope accelerates breakthrough discoveries from the lab to the patient.
Visit us at Booth No. 22095 to learn more about our expanding impact and career opportunities.
R.S.V.P. Now for an Evening with City of Hope
Sunday, May 31, 2026
7 to 8:30 p.m. CDT
The Ritz-Carlton
Ritz-Carlton Ballroom
160 E. Pearson Street
Chicago, Illinois 60611
Join City of Hope leaders, physicians, scientists, physician relations and recruitment teams.
Hors d’oeuvres and drinks will be served.
Official meeting badge must be worn for admittance.
Email or call to R.S.V.P. by May 25, 2026.
Hosted by
Marcel van den Brink is president of City of Hope Los Angeles and National Medical Center and serves as chief physician executive. A globally recognized leader in bone marrow transplantation and microbiome and cancer immunotherapy, he is widely respected for his collaborative leadership as well as
Meet and Greet with Our Renowned Experts
Saturday, May 30, 12:30 to 1 p.m., CDT
Division Chief, Thoracic Medical Oncology; Professor, Department of Medical Oncology and Therapeutics Research; Dr. Norman and Melinda Payson Professorship in Medical Oncology
Medical Director of GI Medical Oncology, City of Hope Orange County; Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research; Rad Family Chair in Gastrointestinal Oncology
Medical Oncologist and Hematologist; President of Medical Staff; Chief of Department of Medical Oncology, City of Hope Chicago Cancer Center
Sunday, May 31, noon to 12:30 p.m., CDT
VP & Chief Pharmacy Officer
Pharmacy Administration
Monday, June 1, 12:30 to 1 p.m., CDT
Medical Oncologist; Division Chief, Genitourinary Disease Program; Professor, Department of Medical Oncology & Therapeutics Research
Presentations and Awards
Featured Abstract Presentations
Hematologic Malignancies — Lymphoma and Chronic Lymphocytic Leukemia
May 30, 5:12 to 5:24 p.m. CDT
Abstract 7007: Mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL): Updated efficacy and safety from the phase 3 SUNMO study including in second-line (2L) versus third-line plus (3L+) patient subgroups.
Genitourinary Cancer — Prostate, Testicular and Penile
May 31, 4:42 to 4:48 p.m. CDT
Abstract 5014: A phase 1, first-in-human (FIH) study evaluating the safety, pharmacokinetics, and efficacy of ABBV-969 in patients with metastatic castration-resistant prostate cancer (mCRPC).
Genitourinary Cancer — Kidney and Bladder
Gastrointestinal Cancer — Gastroesophageal, Pancreatic, and Hepatobiliary
June 1, 1:45 to 1:51 p.m. CDT
Abstract 4012: Randomized phase II trial of olaparib and pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2) mutations: SWOG S2001.
June 1, 2:15 to 2:21 p.m. CDT
Abstract 4015: Tegavivint, a downstream Wnt/β-catenin inhibitor: Dose-finding results from a phase 1/2 trial in advanced hepatocellular carcinoma (aHCC).
City of Hope Experts to Contribute Scientific Perspective Across Plenary, Oral and Education Sessions
Hematologic Malignancies — Plasma Cell Dyscrasia
May 29, 4:21 to 4:33 p.m. CDT
Discussion of Abstracts 7503, 7504 and 7505: Raising the Bar in Newly Diagnosed Multiple Myeloma: Depth, Duration and Risk
Lung Cancer
May 30, 3 to 3:40 p.m. CDT
Case-Based Panel: One Patient, Many Pathways: Management Options in ALK-Positive Non–Small Cell Lung Cancer From Early Stage to Advanced Disease
Hematologic Malignancies — Lymphoma and Chronic Lymphocytic Leukemia
May 30, 5:36 to 5:48 p.m. CDT
Discussion of Abstracts 7006, 7007 and 7008: Tailoring Immunotherapy for Relapsed Lymphoma
Special Sessions (Plenary)
May 31, 2:25 to 2:37 p.m. CDT
Discussion of LBA3: Event-free survival with adjuvant selpercatinib in stage-IB-IIIA RET fusion-positive NSCLC: Primary results of the phase 3 LIBERTTO-432 trial
Special Sessions
June 1, 9 to 9:15 a.m. CDT
Highlights of the Day: Highlights in Prostate Cancer: Moving Towards Personalized Treatment Across the Spectrum of Prostate Cancer
Genitourinary Cancer — Kidney and Bladder
June 1, 5:15 to 5:30 p.m. CDT
Education Session: Frontline Treatment Strategies in Papillary Renal Cell Carcinoma
City of Hope Leaders Honored with Top ASCO Distinctions
- John Carpten, Ph.D., City of Hope chief scientific officer, has been named the recipient of the 2026 Allen Lichter Visionary Leader Award from the American Society of Clinical Oncology.
- Stephen T. Rosen, M.D., City of Hope Executive Vice President and Director Emeritus, has been named the recipient of the Lifetime Cancer Mavericks Award from the Association for Value-Based Cancer Care.
Since ASCO 2025, three City of Hope faculty have been named Fellows of the American Society of Clinical Oncology (FASCO), recognizing outstanding leadership and contributions to the oncology community.
- Arjun Gupta M.D., F.A.S.C.O., Medical oncologist, City of Hope Cancer Center Phoenix
- Tanya Barauskas Dorff, M.D., F.A.S.C.O., Medical oncologist; Division Chief, Genitourinary Disease Program
- Walter Stadler, M.D., F.A.C.P., F.A.S.C.O., Chief scientific officer, City of Hope Cancer Center Chicago
Resources
In the global pursuit of scientific miracles in the fight against deadly diseases, the Beckman Research Institute of City of Hope is among those leading the charge. Its world-renowned staff have been responsible for fundamentally expanding the world’s understanding of how biology affects diseases such as cancer, HIV/AIDS and diabetes.
City of Hope’s clinical training programs offer excellent opportunities for physicians interested in expanding their knowledge base and clinical expertise in specialty and subspecialty areas. Our clinical fellowships and residencies offer intensive didactic as well as hands-on training by instructors who have made significant contributions to cancer research and clinical practice.
We’re aggressively pursuing ways to help our patients right now — not years from now. That immediacy of focus makes City of Hope a worldwide leader in administering clinical trials. Each year, we conduct more than 730 clinical trials, enrolling more than 5,900 patients.
One of the most promising areas of cancer research and treatment is known as immunotherapy, in which a patient’s own immune system is enlisted in the fight against cancer. This approach is more than just a narrow field of study at City of Hope. It is the central component of groundbreaking research and clinical trials currently underway.
City of Hope has joined forces with the TGen to accelerate the speed with which scientists and medical staff convert research discoveries into cures for patients. The alliance is based on a simple premise: City of Hope provides a state-of-the-art clinical setting in which to advance genomic breakthroughs made by TGen.
We are a leader in clinical and translational research, most notably in antibody-based therapy, CAR T cell therapy and bone marrow transplant approaches. When you refer your patient to City of Hope, you can do so with the utmost confidence that our staff will provide the best care possible for your patient.
City of Hope is ever-expanding — whether it’s at our main campus in Duarte, California, the Orange County campus or one of our 30+ clinical network locations. In order to provide premier care throughout Southern California, we seek physicians with a passion for high-quality patient care.
Hosted by Sumanta (Monty) Pal, M.D., F.A.S.C.O., co-director of the Kidney Cancer Program on the Duarte campus, the podcast, "On the Edge of Breakthrough: Voices of Cancer Research" features world-leading oncology experts who explore the latest scientific research and clinical innovations shaping the future of cancer treatment and care.